Thymosin β4

Tβ4 · TB4 · T-β-4 · Parent molecule of TB-500

"The most abundant intracellular peptide in most mammalian cells — TB-500 is derived from its most active region. While TB-500 captures the actin-regulatory mechanism, the full Thymosin β4 protein adds cardiac regeneration, corneal healing, angiogenesis, and broader immunomodulatory functions that the fragment cannot replicate."

Type

43 aa · 4,964 Da · endogenous

vs TB-500

TB-500 = Tβ4(17-23) actin-binding fragment

Status

UK: not illegal to buy or possess · WADA: prohibited at all times · US FDA: not approved · Fast Track designation for corneal wound healing

Key data

Cardiac progenitor activation · corneal healing

Protocol summary

Community dose

2–10 mg/wk SubQ (full Tβ4)

Topical Phase 2

Stasis / pressure ulcers

Cycle

4–8 weeks then break (community)

Community-reported

2–10 mg/week SubQ (full Tβ4) · 4–8 week cycles · often paired with BPC-157

Full-length Tβ4 is distinct from TB-500 fragment — different mechanism breadth

How we read the evidence

Full-length 43-amino-acid Tβ4 protein · NOT the same as TB-500 fragment · solid topical wound-healing Phase 2 evidence · most mechanism work uses full-length, not the fragment

Animal evidence

Substantial. Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide present in nearly every cell type — released by platelets at injury sites and initiating the repair cascade. Mechanism: G-actin sequestration regulating cell shape and movement; promotes cell migration, angiogenesis, anti-apoptotic signalling, anti-inflammation. Animal models — rat full-thickness wound, diabetic mice, aged mice, steroid-treated rats — show 42% increase in re-epithelialisation at day 4 and 61% by day 7, improved wound contraction, increased collagen deposition and new blood vessel formation. Keratinocyte migration stimulated 2–3-fold over baseline at picogram doses (extraordinarily small) in cell culture. Cardiac repair after experimental MI, corneal wound healing (Sosne et al. 2007 Clinical Ophthalmology), tendon and muscle recovery models.

Community & clinical practice

Important distinction: full-length Tβ4 is NOT the same as TB-500 (the 7-amino-acid fragment commonly sold as 'thymosin beta-4' in research vendors) — see the separate TB-500 entry on this platform for the fragment-specific dose, mechanism caveats, and protocol. Most community use of 'thymosin beta-4' is actually the TB-500 fragment, not the full-length protein. The full-length protein is technically demanding and expensive to synthesise, so it is rarely sold as a research peptide. Topical formulations of full-length Tβ4 have been used in Phase 2 ulcer trials but are not commercially available as research products.

Human trial data

Substantial Phase 2 topical evidence. Two Phase 2 clinical trials of full-length Tβ4 in stasis and pressure ulcers found that healing was accelerated by almost a month in patients who did heal (Pubmed 23050815). NCT00382174 — pressure ulcer Phase 2 trial. NCT00598871 — Phase 2 corneal wound trial in diabetic patients post-vitrectomy (terminated due to slow recruitment, not safety). Initial Phase 1 safety trial: 15 healthy volunteers received topical Tβ4 at 250, 500, or 1,000 μg/5 mL or placebo for 28 days — no significant adverse events. Sosne et al. 2007 corneal wound healing work. Most published mechanism evidence uses full-length Tβ4 protein, not the TB-500 fragment — the assumption that the fragment fully reproduces the parent protein's effects is not fully settled.

Regulatory status

Not FDA-approved. Full-length Tβ4 has been investigated as a topical formulation by ReGenTree and others but has not achieved regulatory approval. The TB-500 fragment was placed in FDA 503A Category 2 in 2023 and removed from that category effective late April 2026; FDA's Pharmacy Compounding Advisory Committee scheduled to review TB-500 on July 23, 2026 to consider 503A Bulks List addition. WADA-banned for tested athletes (TB-500 specifically; the analytical methods detect the fragment).

Convergence

Full-length thymosin beta-4 has the strongest mechanism evidence in the Tβ family — solid Phase 2 topical wound-healing data in stasis and pressure ulcers, well-characterised G-actin biology, and decades of published work. But what most users buy and inject as 'thymosin beta-4' is the TB-500 fragment, which is biologically distinct and has its own evidence framework. See the TB-500 entry for fragment-specific details. Pep IQ flags this honestly: the parent protein's evidence is real, the topical Phase 2 ulcer trials accelerated healing by almost a month, but the leap from full-length topical use to fragment SubQ injection involves substantial extrapolation. Members considering 'thymosin beta-4' should be clear which form they're using.

Origin & Background

The complete molecule — beyond what TB-500 can do

Thymosin β4 (Tβ4) is a 43-amino acid, 4,964 Da peptide — the most abundant intracellular actin-sequestering protein in most mammalian cells. It was first isolated from thymic tissue but is now known to be expressed ubiquitously. Every cell in the body uses it to regulate the equilibrium between monomeric G-actin and filamentous F-actin — the dynamic balance that governs cell shape, motility, and division.

TB-500 (the most widely used research peptide for tissue repair) is a synthetic fragment derived from the actin-binding region of Tβ4, specifically amino acids 17-23 (LKKTETQ). TB-500 captures the primary actin-sequestering mechanism and is more stable and practical than the full protein. However, Tβ4 has multiple functional domains beyond the actin-binding sequence: N-terminal domains involved in cardiac progenitor activation, C-terminal sequences relevant to corneal healing, and middle domains that interact with integrin-linked kinase (ILK) and drive angiogenesis. None of these are present in TB-500.

The most compelling Tβ4 research goes beyond tissue repair. The Bhattacharya lab (UCL) demonstrated that Tβ4 activates dormant epicardial progenitor cells after myocardial infarction in mice — priming them to regenerate cardiac muscle. RegeneRx Biopharmaceuticals ran a Phase 1/2 clinical programme for Tβ4 in corneal wound healing, receiving FDA Fast Track designation, before funding constraints halted development.

Tβ4 vs TB-500 — which to use: TB-500 is more practical for tissue repair (more stable, better characterised for that application, cheaper). Full Tβ4 is theoretically better if the goal includes cardiac regeneration potential, corneal healing, or the full angiogenic mechanism — but the practical differences in human protocols are not well-characterised. Most community users use TB-500 for convenience; full Tβ4 is rarer and more expensive.

Science & Mechanism

Multiple domains, multiple mechanisms

Mechanism of Action

Actin sequestration (shared with TB-500): The LKKTETQ sequence (Tβ4 17-23) binds G-actin monomers, maintaining the cellular pool of unpolymerised actin available for dynamic cytoskeletal remodelling. This enables cell migration to injury sites, cell division, and tissue repair. This is TB-500's mechanism — but it is only one of Tβ4's.

ILK (Integrin-Linked Kinase) activation: Tβ4 interacts with ILK, activating downstream signalling that promotes endothelial cell differentiation and migration — the primary mechanism driving Tβ4-induced angiogenesis. New blood vessel formation is essential for healing tissue that lacks vasculature.

Epicardial progenitor activation (cardiac): This is Tβ4's most extraordinary property. After myocardial infarction, dormant epicardial cells can be reprogrammed into cardiac muscle cells by Tβ4. This does NOT occur with TB-500 — it requires the full protein. Bhattacharya (2011) demonstrated that priming with Tβ4 before MI activated these progenitors, and re-treatment after MI induced their differentiation into cardiomyocytes.

Corneal wound healing: Tβ4 stimulates re-epithelialization of the cornea through promoting corneal epithelial cell migration, reducing inflammation, and stimulating angiogenesis in the limbal region. RegeneRx's Phase 1/2 corneal programme (RGN-259, ophthalmic Tβ4) showed improved healing vs standard care.

Anti-inflammatory and NF-κB suppression: Tβ4 inhibits NF-κB-mediated inflammatory gene expression, reducing inflammatory cytokine production at injury sites. This anti-inflammatory effect complements the repair mechanisms rather than suppressing the immune response needed for healing.

Benefits & Evidence

What the data shows

❤️

Cardiac progenitor activation

Bhattacharya (2011, Nature): Tβ4 pretreatment activated dormant epicardial progenitor cells; post-MI treatment induced differentiation into cardiomyocytes. Demonstrated in mouse MI models. Bhattacharya group published follow-up data through 2023 extending these findings. Human translation not yet demonstrated.

● Moderate — compelling mouse data · no human trials

👁️

Corneal wound healing

RegeneRx Phase 1/2 (RGN-259): ophthalmic Tβ4 solution showed improved corneal healing vs standard care. FDA Fast Track designation granted. Development paused due to funding. 2025 publication: engineered tandem Tβ4 peptide promoted corneal wound healing in preclinical models.

● Moderate — Phase 1/2 human data + FDA Fast Track

🩹

Tissue repair and healing

Multiple preclinical studies across tissue types (tendon, muscle, cardiac, corneal). Injectable Tβ4-modified hyaluronic acid with exosomes (ACS Nano 2025): promoted stem cell homing for regeneration. The full protein adds ILK-mediated angiogenesis to the actin mechanism TB-500 provides.

● Moderate — preclinical + small human data

Things to know

Risks & considerations

Mild

Injection site reactions — mild, transient redness and swelling. Common with SubQ administration as with all injectable peptides.

Serious

WADA prohibited at all times — as a peptide hormone and growth factor, Tβ4 is prohibited in competition. Detection methods exist.

Unknown

Cardiac progenitor activation in healthy adults — activating epicardial progenitors in a heart without acute MI injury has not been studied. The theoretical concern of inappropriate cardiac remodelling in healthy subjects is uncharacterised.